- Home
- RMTI vs MAIA Comparison
RMTI vs MAIA Comparison
Compare RMTI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMTI | MAIA |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 49.3M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RMTI | MAIA |
|---|---|---|
| Price | $0.90 | $1.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 260.5K | ★ 551.5K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.89 | 29.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $101,489,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.38 | N/A |
| 52 Week Low | $0.78 | $0.87 |
| 52 Week High | $2.10 | $3.19 |
Technical Indicators
Market Signals| Indicator | RMTI | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 36.14 |
| Support Level | $0.80 | $1.20 |
| Resistance Level | $1.02 | $1.69 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 14.54 | 8.57 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.